M&A / Deals Sky-high Parabilis, Kailera IPOs spur optimism–but only for derisked biotechs pharminent June 11, 2026
Clinical Data Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test pharminent June 11, 2026
M&A / Deals Beren pockets $300m to take Niemann-Pick disease therapy to market pharminent June 11, 2026
Regulatory Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug pharminent June 10, 2026
M&A / Deals Alzecure enters collaboration and with Lilly for Alzheimer’s project pharminent June 9, 2026
Clinical Data ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data pharminent June 9, 2026
M&A / Deals GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year pharminent June 9, 2026
Regulatory ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval pharminent June 9, 2026
Regulatory Pfizer’s Hympavzi secures FDA expanded indications for haemophilia pharminent June 9, 2026
M&A / Deals J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B pharminent June 8, 2026
Commercial ADA ’26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option pharminent June 8, 2026
Clinical Data ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction pharminent June 8, 2026
Commercial Lilly and Novo face off at ADA 2026 as others seek to compete in obesity pharminent June 5, 2026
Policy / Pricing The next FDA commissioner must be a champion for gene therapies pharminent June 5, 2026
Market Access Medicare Advantage in 2026: Premiums, Out-of-Pocket Limits, Supplemental Benefits, and Prior Authorization pharminent June 5, 2026
Clinical Data Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data pharminent June 5, 2026
Policy / Pricing Stakeholders want Makary’s voucher program paused, call for FDA independence pharminent June 5, 2026
Pipeline Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? pharminent June 5, 2026
Regulatory Biogen’s salanersen gains FDA breakthrough therapy designation for SMA pharminent June 5, 2026
M&A / Deals Regeneron deepens relationship with CytomX, adding up to $2B and eight targets pharminent June 4, 2026
Clinical Data Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity pharminent June 4, 2026
